<unk>  should not be used within 14 days of using a monoamine oxidase inhibitor (MAOI) such as phenelzine due to the potential for hypertensive crisis or serotonin syndrome to develop. Its use in those taking potent CYP2D6 inhibitors such as fluoxetine, paroxetine, sertraline, duloxetine, bupropion, and quinidine is recommended against owing to the potential for its accumulation in the absence of full CYP2D6 catalytic activity. Hepatic enzyme inducers such as carbamazepine, phenytoin, and barbiturates are advised against in patients receiving TCAs like<unk>  owing to the potential for problematically rapid metabolism of<unk>  to occur in these individuals. Sympathomimetic agents may have their effects potentiated by TCAs like<unk> .<unk>  also may potentiate the adverse effects of anticholinergic agents such as benztropine, atropine and hyoscine (scopolamine). Tolazamide, when used in conjunction with<unk>  has been associated with a case of severe hypoglycaemia in a type II diabetic individual. Cimetidine may influence the absorption of<unk> . Alcohol may potentiate some of the CNS depressant effects of<unk> . Antihypertensive agents may have their effects mitigated by<unk> . Cotreatment with CNS depressants such as the benzodiazepines can cause additive CNS depression. Co-treatment with thyroid hormones may also increase the potential for adverse reactions.
Doxepin
Chlorpropamide
Pheniramine
Mebanazine
Bromazine
Propranolol
Metkefamide
Bolazine